[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Scripps Translational Science Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":229},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,45,72,96,119,142,161,186,206],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100642958","digital-lifestyle-coaching-for-alzheimers-disease-prevention-in-apoe4-carriers-100642958",false,"NCT07646054","Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers","Wellderly Brain - Alzheimer's Disease Prevention With Lifestyle Coaching Intervention: A Randomized Clinical Trial","WellderlyBrain","Inclusion Criteria:\n\n* Current 23andMe Research participant with APOE4 positivity genetic variant\n* Age 60 to 80 at time of consent\n* Have access to an Android or Apple iPhone smartphone device and able to download study apps\n* Lives in the United States and able to send and receive US Mail\n* Able and willing to perform a self-administered saliva test at screening\\*for organic outreach only.\n* Able and willing to perform a self-administered finger prick blood collection at three time points throughout the study.\n\nExclusion Criteria:\n\n* Non-English speaking\n* Lives outside of the United States\n* Currently taking or planning on taking GLP-1 medications (Exenatide, Liraglutide, Albiglutide, Dulaglutide, Semaglutide or Tirzepatide) within the next 12 months\n* Established diagnosis of Mild Cognitive Impairment, Alzheimer's Disease or other Neurodegenerative Disease (Parkinson's Disease, Amyotrophic Lateral Sclerosis, Huntington's Disease, Multiple Sclerosis or Frontotemporal Dementia).\n* Current or past Oura Ring user (any Oura Ring use in the last 12 months)","ALL","60 Years","80 Years",{"count":21,"type":22},1200,"ESTIMATED","INTERVENTIONAL",[25],"NA","Wellderly Brain is a randomized, direct-to-participant trial evaluating whether a virtually delivered, multidomain lifestyle coaching intervention can favorably impact plasma biomarkers of Alzheimer's disease (AD) in adults aged 60-80 with APOE4 positivity or elevated polygenic risk. Participants are recruited through 23andMe and enrolled via the MyDataHelps platform. Following genetic eligibility screening, 1,200 participants will be randomized to either a digital lifestyle coaching arm (UCardia) or an education-only control arm. The intervention consists of 16 virtual coaching sessions delivered over 52 weeks. All participants will wear an Oura Ring for continuous health monitoring and provide dried blood samples at baseline, 6 months, and 12 months for plasma p-tau217 and proteomic profiling via the NULISAseq CNS Disease Panel. Saliva samples will be collected for epigenetic aging analysis. The study duration is 14-16 months per participant.",[28,29],"Mild Cognitive Impairment (MCI)","Alzheimer Disease (AD)",[31,29],"Alzheimers","NOT_YET_RECRUITING","2026-06-09",{"date":35,"type":36},"2026-06-12","ACTUAL",{"date":38,"type":22},"2026-07-06",{"date":40,"type":22},"2028-12-31",{"name":42,"class":43},"Scripps Translational Science Institute","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":44},"100496198","the-long-covid-19-wearable-device-study-100496198","NCT05741112","The Long COVID-19 Wearable Device Study","Inclusion Criteria:\n\n* Is at least 18 years old.\n* Has a self\u002Fand or physician diagnosis of:\n* Long COVID (based on the WHO working definition),\n* ME\u002FCFS (myalgic encephalomyelitis \u002F chronic fatigue syndrome, self-diagnosis based on IOM criteria), and\u002For\n* POTS (Postural Orthostatic Tachycardia Syndrome).\n* Is interested in tools to manage ME\u002FCFS, POTS, and\u002For Long COVID symptoms.\n* Owns a wearable device they are willing to use for this study or does not own a device and agrees to utilize a study-provided one.\n* Agrees to wear the device throughout the study period, share the data with the study, and sync data at least weekly.\n* Has access to a smartphone or tablet to enable syncing wearable data and viewing device feedback.\n* Agrees to disclose involvement in other ME\u002FCFS, POTS, and\u002For Long COVID interventions such as medical treatment, self-management, and other interventional studies.\n* Agrees to complete at least 75% of the study surveys.\n\nExclusion Criteria:\n\n* As long as they meet inclusion there is no exclusion","18 Years",{"count":53,"type":22},100500,[25],"To further characterize Long COVID-19 by collecting data from individuals who already own wearable devices or are provided with a wearable device along with basic and enhanced educational materials to determine if both can improve Long COVID-19 symptom management and post-exertional malaise.",[57,58,59,60,61,62],"Long COVID","Postural Orthostatic Tachycardia Syndrome","Dysautonomia","Myalgic Encephalomyelitis","Chronic Fatigue Syndrome","Long Covid19","RECRUITING","2025-05-09",{"date":66,"type":36},"2025-05-11",{"date":68,"type":36},"2023-11-16",{"date":70,"type":22},"2025-12-01",{"name":42,"class":43},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":44},"100222046","molecular-autopsy-study-100222046","NCT02168088","Molecular Autopsy Study","Molecular Autopsy for Sudden Cardiovascular Death","Inclusion Criteria:\n\n* Index case age between birth - 45 years\n* Clinical presentation of sudden \u002F unexplained death (believed to be cardiac in nature OR secondary to a massive unprovoked pulmonary embolism with no prior diagnosis of prothrombotic disease)\n\nExclusion Criteria:\n\n* Premature death secondary to murder, suicide or external causal event\n* Premature death thought secondary to known chronic comorbid medical condition\n* Premature death thought secondary to end-organ failure (kidney, liver, lung) other than heart\n* Previously diagnosed with hypertrophic cardiomyopathy (HCM)\n* Prior myocardial infarction (regardless of stenting or bypass)\n* Prior cerebrovascular accident (stroke or TIA)\n* History of open heart surgery (for any reason)\n* History of severe, untreated hypertensive heart disease\n* History of illicit drug use\n* History of heavy alcohol abuse\n* History of severe pulmonary disease\n* History of morbid obesity","45 Years",{"count":81,"type":22},100,"OBSERVATIONAL","This study seeks to incorporate genetic testing into the postmortem examination of cases of sudden unexplained death.",[85],"Sudden Unexplained Death",[87],"Sudden unexplained death","2025-01-15",{"date":90,"type":36},"2025-01-16",{"date":92,"type":4},"2014-06",{"date":94,"type":22},"2030-06",{"name":42,"class":43},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":103,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":44},"100133275","the-healthy-elderly-longevity-cohort-100133275","NCT01004133","The Healthy Elderly Longevity Cohort","Wellderly","Inclusion Criteria:\n\n1. Age 80 years or older\n2. Eligible for blood draw and\u002For saliva collection\n3. Be reliable, cooperative and willing to comply with all protocol-specified procedures\n4. Able to understand and grant informed consent\n5. Be healthy or have mild medical conditions that may be associated with the normal aging process, including:\n\n   * Hypertension, well controlled (no more than 3 medications)\n   * Osteoporosis, Osteopenia and\u002For osteoarthritis\n   * Benign prostatic hypertrophy\n   * Cataracts, Glaucoma, Macular Degeneration\n   * Dyslipidemia\n   * Hypothyroidism\n   * Pre-diabetes\u002Fimpaired fasting glucose (fasting blood glucose 100-126 mg\u002FdL, if known)\n\nExclusion Criteria:\n\n1. \\\u003C 80 years old\n2. Participants have been previously enrolled in The Scripps Genebank Healthy Elderly Cohort\n3. Treatment with any investigational agents or devices within thirty days preceding enrollment in the study.\n4. Self-reported history or current diagnosis of significant chronic conditions including:\n\n   * Any Cancer (including polycythemia; excluding basal or squamous cell skin cancer).\n   * Coronary Artery Disease\u002FMyocardial Infarction\n   * Stroke\u002FTIA\n   * Deep Vein Thrombosis\u002FPulmonary Embolus\n   * Chronic Renal Disease\u002FHemodialysis\n   * Significant Auto-immune\u002FInflammatory conditions such as (Rheumatoid Arthritis, Lupus, Crohn's, etc.\n   * Alzheimer's\u002FParkinson's\n   * Diabetes (Hemoglobin A1C \\> 6.5 % or fasting glucose \\>126 mg\u002FdL or treated with oral diabetic medication or insulin if known)\n   * Aortic or Cerebral Aneurysm\n5. Currently taking any of the following medications on a regular basis:\n\n   * Oral chemotherapeutic agents (ex.: tamoxifen, doxorubicin, mitoxantrone, bleomycin)\n   * Anti-platelet agents, not including aspirin (ex.: clopidogrel\u002Fplavix, dipyridamole\u002Faggrenox\u002Fpersantine, ticlopidine\u002Fticlid)\n   * Cholinesterase inhibitor for Alzheimer's disease (i.e. donepezil\u002FAricept)\n   * Insulin\n6. Subject has a significant medical condition which, in the Investigator's opinion, may interfere with the patient's optimal participation in the study or would potentially confound interpretation of the individual's phenotype.",true,{"count":105,"type":22},5000,"With the completion of the human genome project, investigators can now explore new questions in human biology. Previously human genetics focused on highly penetrant, Mendelian traits; however, now rare and common variants can be discovered that affect \"common\" diseases that have multi-gene architecture with variable penetrance such as breast cancer, diabetes mellitus, and coronary artery disease. This change took place because investigators now have the tools to illuminate the whole genome at once to discover the genetic variants responsible for different disease phenotypes through statistical differences between populations. Besides disease phenotypes, health can be considered a human phenotype that can be studied. Health is not merely the absence of disease but may be viewed as a dynamic ongoing interplay between the environment and the genome to maintain homeostasis. Individuals often attempt to optimize environmental conditions according to ones genome to maximize their health. All individuals possess potentially beneficial and harmful variants depending on the environment. How this dynamic interplay occurs between the genome and environment requires understanding the boundary conditions of the genetic architecture of health and disease and then modeling the system to simulate the observed data.\n\nThe aging process also affects health. Aging involves a loss of the normal coping responses to internal and external environmental stressors or signals. Investigators now have the tools to uncover from the bottom up the mechanisms involved in maintaining the ability to overcome environmental conditions that can affect health.\n\nAgainst this genomic breakthrough of whole genome association studies, the demographics in the United States are quickly changing. The older population (age \\> 65 years) in 2030 is projected to be twice as large as in 2000 representing nearly 20 percent of the total US population. The first baby boomers turn 65 in 2011 and will challenge all facets of health care in the coming decades. The demographic changes underscore the need to understand the mechanisms that promote health and disease in this cohort. Genomic discoveries will help individuals and may reduce medical costs and benefit society.\n\nIn summary, the objective of this study is to obtain blood and\u002For saliva samples in order to help model health and disease phenotypes through population genomics. The blood and\u002For saliva samples may allow for participants' entire genomes to be sequenced if such comprehensive analysis becomes feasible and economical.",[108],"Healthy",[110,111],"Age 80 or older","No chronic disease",{"date":113,"type":36},"2025-01-17",{"date":115,"type":4},"2007-08",{"date":117,"type":22},"2030-01",{"name":42,"class":43},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":103,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":44},"100454453","research-framework-exploring-sleep-health-100454453","NCT05197738","Research Framework Exploring Sleep Health","REFRESH","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Residing within the United States\n* Ability to use the REFRESH app on the participant's own smartphone device\n\nExclusion Criteria:\n\n* In-ability to consent",{"count":127,"type":22},100000,"This is a digital health study in which participants are recruited to collect sleep and activity data from digital activity trackers. We are also collecting survey\u002Fquestionnaire data on baseline health and sleep characteristics as well as bi-weekly assessments of sleep quality and mood. Overall, we aim to examine how sleep relates to physical and mental health in a large population of activity tracker users.",[130,131,132,133],"Sleep","Sleep Apnea","Obesity","Mood","2024-06-27",{"date":136,"type":36},"2024-06-28",{"date":138,"type":36},"2022-02-15",{"date":140,"type":22},"2041-12-31",{"name":42,"class":43},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":103,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":149,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":44},"100307062","mygenerank-a-digital-platform-for-next-generation-genetic-studies-100307062","NCT03277365","MyGeneRank: A Digital Platform for Next-Generation Genetic Studies","Inclusion Criteria:\n\n* Customer of 23andMe willing to share their 23andMe data\n* User of Apple mobile device\n\nExclusion Criteria:\n\n* Under 18 years old",{"count":127,"type":22},[25],"Many conditions affecting health are caused by a combination of environment, behaviors, and genes. While individuals can alter some factors in their lives to reduce the chances of developing different diseases (e.g., not smoking cigarettes), the contribution from genetic risk encoded by DNA remains with people throughout their lives. Scientists are still trying to determine the entirety of genetic factors that influence disease, but for some conditions it has been shown that the factors identified thus far can begin to identify people at high to low genetic risk. Looking across the genome, scientists can calculate a cumulative genetic risk score - which can be used to rank genetic risk compared to other worldwide populations.\n\nThe goal of this study is to determine how genetic risk influences health decisions and other things that can be controlled in life. The first genetic risk score is calculated for coronary heart disease (CAD). CAD ultimately leads to heart attacks, heart failure and sometimes sudden cardiac death and is the main reason heart disease remains as the number one cause of death worldwide. Other researchers have shown that this genetic risk score can be used to identify people with low, intermediate, and high risk for coronary heart disease. It has also been shown that the use of statins (cholesterol lowering drugs) provides greater benefit and protection against heart attack for people with high genetic risk for coronary artery disease.\n\nLeveraging the Apple ResearchKit and the ResearchKit linked 23andMe API, customers of 23andMe are able to provide researchers access to their genomic data. Participants will use the ResearchKit app to provide consent, view study information, answer surveys, and contact the study team.\n\nParticipants will be asked to complete 3 surveys. One before viewing genetic risk scores, one immediately after viewing scores, and one 6 months after viewing scores.",[152],"Heart Diseases","2024-04-15",{"date":155,"type":36},"2024-04-17",{"date":157,"type":36},"2017-09-26",{"date":159,"type":22},"2030-09",{"name":42,"class":43},{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":103,"sex":167,"minAge":168,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":170,"conditions":171,"keywords":176,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":44},"100292364","powermom-a-healthy-pregnancy-research-community-100292364","NCT03085875","POWERMOM, A Healthy Pregnancy Research Community","Inclusion Criteria:\n\n* Adults, 16 years of age or older\n* Pregnant women or within 8 weeks postpartum\n* Currently live within the United States\n* Own, and comfortable using, a smartphone or tablet\n\nExclusion Criteria:\n\n• Inability to consent","FEMALE","16 Years",{"count":127,"type":22},"This study will take advantage of the open source framework of ResearchKit developed by Apple to bring research directly to participants. Using the ResearchKit platform as well as a stand alone app available for Android and HTML, it makes it easier to enroll large numbers of participants and carry out real-world health research to answer questions important to a broad population.",[172,173,174,175],"Pregnancy Related","Weight Change, Body","Health Problems in Pregnancy","Behavior",[177,178,179],"Weight Change","Healthy Pregnancy","Physiologic Sensors",{"date":155,"type":36},{"date":182,"type":36},"2017-03-16",{"date":184,"type":22},"2027-07-31",{"name":42,"class":43},{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":167,"minAge":51,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":23,"phases":194,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":44},"100534908","the-sequencing-for-detection-in-congenital-heart-disease-sd-chd-study-100534908","NCT06244940","The Sequencing for Detection in Congenital Heart Disease (SD-CHD) Study","Inclusion Criteria:\n\n* Pregnant individual with ongoing pregnancy with prenatally detected fetal CHD\n* Desire for genetic diagnosis and clinical plan for amniocentesis or chorionic villus sampling\n\nExclusion Criteria:\n\n* Gestational age of 38 weeks or greater\n* Clinical course entirely explained by known chromosomal abnormality or confirmed genetic diagnosis that explains the clinical condition\n* Pregnant persons under 18 years of age",{"count":193,"type":22},200,[25],"This study is enrolling pregnant persons treated at Rady Children's Hospital fetal cardiology program with a prenatal diagnosis of congenital heart disease to look for genetic disorders in the fetus or unborn baby.\n\nCongenital heart disease (CHD) is a group of structural differences to the heart that represent the most common birth defect among liveborn infants world-wide. CHD is the leading cause of birth-defect associated infant death. Prenatal detection allows for delivery planning, postnatal repair, specialized medications, and detailed counseling for parents. Up to one in three fetuses with CHD may have a genetic cause. In babies, knowing about genetic diseases helps patients and doctors provide the best care for their babies. If identified prenatally, this same knowledge may help participants prepare for their location of delivery, meet with specialists, and consider specialized treatments and medications that may be appropriate.\n\nThe diagnostic yield and clinical utility of whole genome sequencing (WGS) in fetuses with prenatally detected congenital heart disease (CHD) will be compared to routine clinical testing in patients choosing amniocentesis or chorionic villus sampling. DNA will be obtained from fetal samples and biological parent blood samples and analyzed according to standard clinical interpretation guidelines. Results will be reported to healthcare providers and patients and measures of clinical utility will be collected. Additionally, measures of stress, anxiety, depression, and perceived utility of information will be assessed by validated survey tools. A historical cohort of patients electing for diagnostic procedures will be used as a comparison population.",[197],"Congenital Heart Disease","2024-02-09",{"date":200,"type":36},"2024-02-13",{"date":202,"type":36},"2024-01-09",{"date":204,"type":22},"2026-10-01",{"name":42,"class":43},{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":213,"enrollmentInfo":214,"targetDuration":4,"studyType":23,"phases":216,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":4},"100452756","prospective-electronic-polygenic-risk-study---second-phase-100452756","NCT05175651","Prospective Electronic Polygenic Risk Study - Second Phase","PEPRS2","Inclusion Criteria:\n\n* 45 ≥ Age \\\u003C 65\n* ASCVD Risk Score \\> 7.5% as defined by the standard pooled cohort equation\n* Access to and ability to use a smartphone\n\nExclusion Criteria:\n\n* Prior diagnosis of coronary disease as defined by prior myocardial infarction (STEMI or NSTEMI), or revascularization (stent or coronary artery bypass grafting)\n* Prior diagnosis or treatment of glaucoma\n* Cerebrovascular disease with history of ischemic stroke, TIA, carotid endarterectomy, carotid artery stenting\n* Peripheral arterial disease with history of claudication, revascularization (stents or bypass)\n* Current and active high-intensity statin prescription (rosuvastatin 20 mg, rosuvastatin 40 mg, atorvastatin 40 mg and atorvastatin 80 mg)\n* Anti-PCSK9 therapy\n* Lipid apheresis therapy\n* Currently enrolled in a clinical trial for lipid lowering therapy\n* Known statin intolerance to 2 or more statins in the past","65 Years",{"count":215,"type":22},10000,[25],"This study will investigate the role of polygenic risk scores (PRS) in preventive health.",[219,220],"Coronary Artery Disease","Glaucoma","2022-11-03",{"date":223,"type":36},"2022-11-07",{"date":225,"type":22},"2023-06",{"date":227,"type":22},"2027-01-15",{"name":42,"class":43},""]